These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 31999935

  • 1. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
    Batur S, Dulger O, Durak S, Yumuk PF, Caglar HB, Bozkurtlar E, Bozkurt S, Tastekin E, Cicin I, Ahiskali R, Rzazade R, Cakir A, Oz B.
    Bosn J Basic Med Sci; 2020 Aug 03; 20(3):329-335. PubMed ID: 31999935
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M.
    J Neurooncol; 2016 Oct 03; 130(1):19-29. PubMed ID: 27436101
    [Abstract] [Full Text] [Related]

  • 4. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM, Helal DS, Sabry NM, Abo El-Nasr M.
    J Egypt Natl Canc Inst; 2018 Dec 03; 30(4):125-131. PubMed ID: 30337185
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer.
    Yang H, Shi J, Lin D, Li X, Zhao C, Wang Q, Zhang L, Jiang T, Zhao S, Liu X, Jia Y, Zhang Y, Cai W, Zhou C.
    Cancer Med; 2018 Jan 03; 7(1):32-45. PubMed ID: 29168339
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.
    Li YM, Yu JM, Liu ZY, Yang HJ, Tang J, Chen ZN.
    Int J Mol Sci; 2019 Oct 17; 20(20):. PubMed ID: 31627272
    [Abstract] [Full Text] [Related]

  • 11. Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, Shim HS, Jung I, Lee CY, Cho BC, Kim HR.
    Lung Cancer; 2019 Oct 17; 136():30-36. PubMed ID: 31421259
    [Abstract] [Full Text] [Related]

  • 12. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
    Steele KE, Tan TH, Korn R, Dacosta K, Brown C, Kuziora M, Zimmermann J, Laffin B, Widmaier M, Rognoni L, Cardenes R, Schneider K, Boutrin A, Martin P, Zha J, Wiestler T.
    J Immunother Cancer; 2018 Mar 06; 6(1):20. PubMed ID: 29510739
    [Abstract] [Full Text] [Related]

  • 13. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.
    Med Sci Monit; 2017 Mar 09; 23():1208-1216. PubMed ID: 28275222
    [Abstract] [Full Text] [Related]

  • 14. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.
    J Thorac Oncol; 2018 Dec 09; 13(12):1884-1896. PubMed ID: 30267840
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L, Cao MF, Zhang X, Dang WQ, Xiao JF, Liu Q, Tan YH, Tan YY, Xu YY, Xu SL, Yao XH, Cui YH, Zhang X, Bian XW.
    Cancer Med; 2019 Dec 09; 8(17):7207-7218. PubMed ID: 31605439
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R, Keam B, Kim S, Kim M, Kim SH, Kim JW, Kim YJ, Kim TM, Jeon YK, Kim DW, Chung DH, Lee JS, Heo DS.
    BMC Cancer; 2019 Jan 07; 19(1):19. PubMed ID: 30616523
    [Abstract] [Full Text] [Related]

  • 20. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR.
    J Thorac Oncol; 2017 May 07; 12(5):814-823. PubMed ID: 28132868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.